U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06842823) titled 'A Study of Navenibart in Participants with Hereditary Angioedema' on Feb. 19.
Brief Summary: This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Hereditary Angioedema (HAE)
Intervention:
DRUG: navenibar...